Insider Selling: BeOne Medicines (NASDAQ:ONC) SVP Sells $107,900.00 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 332 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $325.00, for a total value of $107,900.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Chan Henry Lee also recently made the following trade(s):

• On Wednesday, November 12th, Chan Henry Lee sold 996 shares of BeOne Medicines stock. The shares were sold at an average price of $349.17, for a total value of $347,773.32.
• On Wednesday, October 8th, Chan Henry Lee sold 10,671 shares of BeOne Medicines stock. The shares were sold at an average price of $350.40, for a total value of $3,739,118.40.

BeOne Medicines Stock Performance

NASDAQ ONC opened at $319.06 on Monday. The stock has a fifty day simple moving average of $331.05 and a 200-day simple moving average of $306.05. The company has a current ratio of 2.39, a quick ratio of 2.17 and a debt-to-equity ratio of 0.03. The stock has a market cap of $37.82 billion, a PE ratio of 625.61 and a beta of 0.45. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $170.99 and a twelve month high of $385.22.

Analysts Set New Price Targets

ONC has been the topic of a number of research analyst reports. Zacks Research downgraded shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 28th. Barclays initiated coverage on BeOne Medicines in a research report on Thursday, September 18th. They issued an “overweight” rating and a $385.00 target price on the stock. JPMorgan Chase & Co. upped their price target on BeOne Medicines from $345.00 to $385.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 8th. Citigroup lifted their price objective on BeOne Medicines from $399.00 to $405.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Finally, Citizens Jmp boosted their price objective on BeOne Medicines from $348.00 to $396.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $365.79.

Hedge Funds Weigh In On BeOne Medicines

Institutional investors have recently modified their holdings of the business. Legal & General Group Plc acquired a new stake in BeOne Medicines in the second quarter valued at $13,857,000. Slow Capital Inc. purchased a new position in shares of BeOne Medicines in the 2nd quarter valued at about $4,377,000. Virtus Investment Advisers LLC acquired a new stake in shares of BeOne Medicines during the 2nd quarter worth about $389,000. Public Employees Retirement System of Ohio purchased a new stake in BeOne Medicines during the second quarter worth approximately $3,491,000. Finally, Fox Run Management L.L.C. acquired a new position in BeOne Medicines in the second quarter valued at approximately $496,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.